obesity

News

Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.

News

Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.

News

For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

News

A study has found evidence that 11 cancers are becoming more common among young people in England, and points to a main driving factor.

News

Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.

News

Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.